Willingdon Wealth Management increased its stake in Celgene Co. (NASDAQ:CELG) by 9.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,512 shares of the biopharmaceutical company’s stock after purchasing an additional 4,348 shares during the quarter. Celgene accounts for 1.2% of Willingdon Wealth Management’s investment portfolio, making the stock its 21st largest position. Willingdon Wealth Management’s holdings in Celgene were worth $4,520,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Wedge Capital Management L L P NC increased its holdings in Celgene by 0.8% during the 3rd quarter. Wedge Capital Management L L P NC now owns 389,679 shares of the biopharmaceutical company’s stock valued at $34,872,000 after acquiring an additional 3,176 shares in the last quarter. US Bancorp DE increased its holdings in Celgene by 7.6% during the 3rd quarter. US Bancorp DE now owns 1,054,363 shares of the biopharmaceutical company’s stock valued at $94,356,000 after acquiring an additional 74,017 shares in the last quarter. Anchor Capital Advisors LLC purchased a new position in Celgene during the 3rd quarter valued at about $206,000. Moody National Bank Trust Division increased its holdings in Celgene by 1,068.3% during the 3rd quarter. Moody National Bank Trust Division now owns 82,835 shares of the biopharmaceutical company’s stock valued at $7,412,000 after acquiring an additional 75,745 shares in the last quarter. Finally, Bray Capital Advisors increased its holdings in Celgene by 14.8% during the 3rd quarter. Bray Capital Advisors now owns 15,639 shares of the biopharmaceutical company’s stock valued at $1,400,000 after acquiring an additional 2,011 shares in the last quarter. Institutional investors and hedge funds own 72.98% of the company’s stock.
Celgene stock opened at $74.19 on Friday. Celgene Co. has a 12-month low of $70.09 and a 12-month high of $110.81. The stock has a market cap of $50.07 billion, a price-to-earnings ratio of 10.85, a PEG ratio of 0.44 and a beta of 1.53. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.02 by $0.27. Celgene had a net margin of 19.64% and a return on equity of 108.76%. The business had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.83 billion. As a group, equities research analysts expect that Celgene Co. will post 7.45 EPS for the current fiscal year.
In related news, Director John H. Weiland bought 5,575 shares of the firm’s stock in a transaction that occurred on Tuesday, August 7th. The shares were acquired at an average cost of $89.73 per share, with a total value of $500,244.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ernest Mario sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the completion of the sale, the director now directly owns 44,413 shares in the company, valued at $4,100,208.16. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.
Several research firms have weighed in on CELG. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “strong-buy” rating and set a $102.00 target price for the company in a report on Wednesday, August 1st. Mizuho restated a “buy” rating and set a $129.00 target price on shares of Celgene in a report on Tuesday, July 31st. Cantor Fitzgerald began coverage on shares of Celgene in a report on Monday, October 1st. They set an “overweight” rating and a $100.00 target price for the company. BidaskClub upgraded shares of Celgene from a “hold” rating to a “buy” rating in a report on Thursday, August 16th. Finally, Morgan Stanley raised their target price on shares of Celgene from $91.00 to $93.00 and gave the company an “equal weight” rating in a report on Friday, July 27th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $117.91.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Further Reading: Why do earnings reports matter?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.